Target family: Prostanoid receptors (type: gpcr)
Target: DP<sub>2</sub> receptor

Ligand: 13,14-dihydro-15-keto-PGD2 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2.
Published in: Br J Pharmacol

Ligand: 13,14-dihydro-15-keto-PGD2 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Expression and molecular pharmacology of the mouse CRTH2 receptor.
Published in: J Pharmacol Exp Ther

Ligand: 13,14-dihydro-15-keto-PGD2 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Expression and molecular pharmacology of the mouse CRTH2 receptor.
Published in: J Pharmacol Exp Ther

Ligand: 13,14-dihydro-15-keto-PGD2 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): CRTH2-specific binding characteristics of [3H]ramatroban and its effects on PGD2-, 15-deoxy-Delta12, 14-PGJ2- and indomethacin-induced agonist responses.
Published in: Eur J Pharmacol

Ligand: 13,14-dihydro-15-keto-PGD2 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Identification of determinants of ligand binding affinity and selectivity in the prostaglandin D2 receptor CRTH2.
Published in: J Biol Chem

Ligand: 13,14-dihydro-15-keto-PGF2α (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.3 pKi
Reference (Journal): Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2.
Published in: Br J Pharmacol

Ligand: 15-deoxy-Δ12,14-PGD2 (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.3 pKi
Reference (Journal): Expression and molecular pharmacology of the mouse CRTH2 receptor.
Published in: J Pharmacol Exp Ther

Ligand: 15-deoxy-Δ12,14-PGJ2 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.6 pKi
Reference (Journal): Expression and molecular pharmacology of the mouse CRTH2 receptor.
Published in: J Pharmacol Exp Ther

Ligand: 15-deoxy-Δ12,14-PGJ2 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8.5 pKi
Reference (Journal): Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2.
Published in: Br J Pharmacol

Ligand: 15(R)-15-methyl-PGD2 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 8.899999618530273 pKi
Reference (Journal): CRTH2-specific binding characteristics of [3H]ramatroban and its effects on PGD2-, 15-deoxy-Delta12, 14-PGJ2- and indomethacin-induced agonist responses.
Published in: Eur J Pharmacol

Ligand: 15(R)-15-methyl-PGD2 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 8.899999618530273 pKi
Reference (Journal): 15R-methyl-prostaglandin D2 is a potent and selective CRTH2/DP2 receptor agonist in human eosinophils.
Published in: J Pharmacol Exp Ther

Ligand: 15(R)-15-methyl-PGD2 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 8.899999618530273 pKi
Reference (Journal): Expression and molecular pharmacology of the mouse CRTH2 receptor.
Published in: J Pharmacol Exp Ther

Ligand: 15(S)-15-methyl-PGD2 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.5 pKi
Reference (Journal): Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2.
Published in: Br J Pharmacol

Ligand: AM-461 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.149999618530273 pIC50
Reference (Patent): DP2 ANTAGONIST AND USES THEREOF

Ligand: AM-461 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.279999732971191 pIC50
Reference (Patent): DP2 ANTAGONIST AND USES THEREOF

Ligand: AM-461 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.010000228881836 pIC50
Reference (Patent): DP2 ANTAGONIST AND USES THEREOF

Ligand: ARRY-502 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.590000152587891 pEC50
Reference (Patent): 6-substituted phenoxychroman carboxylic acid derivatives

Ligand: AZD1981 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: yes
Median affinity: 8.369999885559082 pIC50
Reference (Journal): Substituted indole-1-acetic acids as potent and selective CRTh2 antagonists-discovery of AZD1981.
Published in: Bioorg Med Chem Lett

Ligand: compound 51 [Crosignani et al., 2011] (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.15999984741211 pKi
Reference (Journal): Discovery of a Novel Series of CRTH2 (DP2) Receptor Antagonists Devoid of Carboxylic Acids.
Published in: ACS Med Chem Lett

Ligand: Δ12-PGJ2 (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8.2 pKi
Reference (Journal): Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2.
Published in: Br J Pharmacol

Ligand: Δ12-PGJ2 (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.4 pKi
Reference (Journal): Expression and molecular pharmacology of the mouse CRTH2 receptor.
Published in: J Pharmacol Exp Ther

Ligand: fevipiprant (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: yes
Median affinity: 8.989999771118164 pKd
Reference (Journal): QAW039, a slowly dissociating CRTh2 antagonist with potential for improved clinical efficacy.
Published in: Eur Respir J

Ligand: fevipiprant (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: yes
Median affinity: 8.989999771118164 pKd
Reference (Journal): Fevipiprant (QAW039), a Slowly Dissociating CRTh2 Antagonist with the Potential for Improved Clinical Efficacy.
Published in: Mol Pharmacol

Ligand: indomethacin (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1965)
Median affinity:  pKi
Reference (Journal): Expression and molecular pharmacology of the mouse CRTH2 receptor.
Published in: J Pharmacol Exp Ther

Ligand: indomethacin (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1965)
Median affinity:  pKi
Reference (Journal): CRTH2-specific binding characteristics of [3H]ramatroban and its effects on PGD2-, 15-deoxy-Delta12, 14-PGJ2- and indomethacin-induced agonist responses.
Published in: Eur J Pharmacol

Ligand: indomethacin (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1965)
Median affinity:  pKi
Reference (Journal): Identification of determinants of ligand binding affinity and selectivity in the prostaglandin D2 receptor CRTH2.
Published in: J Biol Chem

Ligand: indomethacin (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1965)
Median affinity:  pKi
Reference (Journal): Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2.
Published in: Br J Pharmacol

Ligand: L-888,291 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.32 pKi
Reference (Journal): Identification of a potent and selective synthetic agonist at the CRTH2 receptor.
Published in: Mol Pharmacol

Ligand: L-888,607 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 9.1 pKi
Reference (Journal): Identification of a potent and selective synthetic agonist at the CRTH2 receptor.
Published in: Mol Pharmacol

Ligand: PGD2 (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Expression and molecular pharmacology of the mouse CRTH2 receptor.
Published in: J Pharmacol Exp Ther

Ligand: PGD2 (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2.
Published in: Br J Pharmacol

Ligand: PGD2 (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): CRTH2-specific binding characteristics of [3H]ramatroban and its effects on PGD2-, 15-deoxy-Delta12, 14-PGJ2- and indomethacin-induced agonist responses.
Published in: Eur J Pharmacol